A Nature Communications analysis of more than 100,000 multi‑cancer detection tests released real‑world insights into sensitivity, tissue‑of‑origin signals, and clinical utility across cancer types. The cross‑study dataset highlighted detection patterns and informed potential use cases for population‑level screening. Concurrently, Guardant Health announced commercial movement into the multi‑cancer blood‑screening market with its Shield MCD assay and described growth in real‑world adoption for its colorectal cancer application. Together, the academic dataset and Guardant’s market push illustrate how clinical evidence and commercial deployment are converging, raising questions about screening guidelines, confirmatory diagnostics, and payer coverage as firms seek to scale multi‑cancer tests.